Veru (VERU) Q1 2025 earnings summary

Executive summary

• Completed sale of FC2 business for $18M, marking a strategic shift to focus exclusively on late-stage biopharmaceutical development, primarily enobosarm and sabizabulin for obesity, muscle preservation, and cardiometabolic diseases.

• Reported positive topline results from Phase 2b QUALITY study for enobosarm (including in combination with semaglutide), meeting primary and key secondary endpoints in older overweight/obese patients.

• Announced new indication for sabizabulin targeting inflammation in atherosclerotic cardiovascular disease, with FDA pre-IND meeting completed and Phase 2 study planned.

• Independent Data Monitoring Committee recommended continuation of the QUALITY extension study after safety review.

• Company is not profitable, has negative cash flow from operations, and faces substantial doubt about its ability to continue as a going concern for the next 12 months.

Financial highlights

• Net loss from continuing operations was $1.8M ($0.01/share) vs. $7.7M ($0.08/share) year-over-year; total net loss increased to $8.9M ($0.06/share) from $8.3M ($0.08/share).

• Net loss from discontinued operations (FC2) was $7.1M, including a $4.2M loss on sale.

• R&D expenses rose to $5.7M from $1.7M year-over-year, mainly due to enobosarm clinical trial costs.

• Cash, cash equivalents, and restricted cash totaled $26.6M at quarter-end, with net working capital of $22M.

• Cash used in operations was $11.3M for the quarter; cash from investing activities was $17.2M, mainly from the FC2 sale.

Outlook and guidance

• Current cash is sufficient to fund operations through year-end 2025, covering the enobosarm Phase 2b extension study data readout, but additional capital will be needed beyond the next 12 months.

• Topline results from the Phase 2b QUALITY extension study expected in Q2 2025; plans to advance enobosarm to Phase 3 clinical trials with 52-week duration, pending FDA discussions.

• Developing a novel modified release oral formulation of enobosarm, with Phase 1 bioavailability trial anticipated in H1 2025.

• Sabizabulin IND submission for atherosclerotic cardiovascular disease planned for H1 2026, subject to funding.

• Plans to present full clinical data at scientific conferences after extension study completion.